Quirk Gerald E 4
4 · Syros Pharmaceuticals, Inc. · Filed Apr 2, 2024
Insider Transaction Report
Form 4
Quirk Gerald E
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-27+22,500→ 46,803 total - Exercise/Conversion
Restricted Stock Units
2024-03-27−22,500→ 0 total→ Common Stock (22,500 underlying) - Tax Payment
Common Stock
2024-03-28$5.59/sh−7,046$39,387→ 39,757 total
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 11, 2022. These restricted stock units vested as to one half (50%) of the shares on October 11, 2023, and vested as to one half (50%) of the shares on March 27, 2024.